宝济药业-B(02659.HK)预计12月10日上市 引入安科生物等基石

Group 1 - The company, Baoji Pharmaceutical-B (02659.HK), plans to globally offer 37.9117 million H-shares, with 3.7912 million shares available in Hong Kong and 34.1205 million shares for international distribution, subject to reallocation [1] - The offering price is set at HKD 26.38 per share, with a trading unit of 100 shares, and the shares are expected to commence trading on the Hong Kong Stock Exchange on December 10, 2025 [1] Group 2 - The company, established in 2019, focuses on four strategic areas: large-volume subcutaneous delivery, antibody-mediated autoimmune diseases, assisted reproduction, and recombinant biopharmaceuticals [2] - The pipeline includes 12 self-developed products, with three core products: SJ02 (a long-acting recombinant human follicle-stimulating hormone), KJ017 (a recombinant hyaluronidase), and KJ103 (an innovative recombinant immunoglobulin G degrading enzyme) [2] Group 3 - The company has entered into cornerstone investment agreements, with cornerstone investors agreeing to subscribe for shares totaling HKD 200.6 million, which equates to approximately 7.6041 million shares at the offering price [3] - The net proceeds from the global offering are expected to be approximately HKD 921.5 million, with allocations of 53.5% for R&D and commercialization of core products, 17.7% for advancing other pipeline products, 8.4% for optimizing the proprietary synthetic biology platform, 10.4% for enhancing production capacity, and 10.0% for working capital and general corporate purposes [3]